NCT00543816终止3 期
MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 100
研究概览
简要总结
This study will look to see if MK0767 works better than placebo in controlling blood sugar in patients with Type 2 Diabetes who are taking insulin but do not have adequate control of their blood sugar.
This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 Diabetes with inadequate glycemic control
- •Patient is on stable insulin therapy alone or with one oral antidiabetic agent
- •Male or non-pregnant female 21 years or older
- •Total daily dose of insulin must be less than or equal to 30 but not greater than or equal to 200 units/day
排除标准
- •Have a history of type 1 diabetes mellitus
- •History of ketoacidosis who are being treated with insulin
- •Are taking 2 or more antidiabetic agents in combination with insulin
研究者
相似试验
终止
3 期
MK0767 and Sulfonylurea Combination Study (0767-027)Diabetes Mellitus, Type 2NCT00543491Merck Sharp & Dohme LLC129
终止
2 期
MK0767 in Type 2 Diabetes (0767-012)Type 2 Diabetes MellitusNCT00543556Merck Sharp & Dohme LLC514
终止
3 期
MK0767 and Metformin Combination Study (0767-028)Diabetes MellitusNCT00543738Merck Sharp & Dohme LLC114
终止
3 期
Study A - MK0767 Monotherapy StudyDiabetes Mellitus, Type 2NCT00543517Merck Sharp & Dohme LLC99
已完成
3 期
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2ObesityNCT01306214Boehringer Ingelheim566